{"protocolSection":{"identificationModule":{"nctId":"NCT02669121","orgStudyIdInfo":{"id":"NOR-211"},"secondaryIdInfos":[{"id":"U1111-1175-9077","type":"REGISTRY","domain":"WHO"}],"organization":{"fullName":"Takeda","class":"INDUSTRY"},"briefTitle":"Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults","officialTitle":"Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years"},"statusModule":{"statusVerifiedDate":"2021-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-06-14","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-06-16","type":"ACTUAL"},"completionDateStruct":{"date":"2018-06-16","type":"ACTUAL"},"studyFirstSubmitDate":"2016-01-27","studyFirstSubmitQcDate":"2016-01-27","studyFirstPostDateStruct":{"date":"2016-01-29","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-05-14","resultsFirstSubmitQcDate":"2021-05-14","resultsFirstPostDateStruct":{"date":"2021-06-10","type":"ACTUAL"},"dispFirstSubmitDate":"2019-05-30","dispFirstSubmitQcDate":"2019-05-30","dispFirstPostDateStruct":{"date":"2019-06-05","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-05-14","lastUpdatePostDateStruct":{"date":"2021-06-10","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Takeda","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the efficacy of the Norovirus (NoV) GI.1/GII.4 bivalent virus-like particle vaccine against moderate or severe acute gastroenteritis (AGE) due to genotype-specific (GI.1 and GII.4) NoV strains.","detailedDescription":"The vaccine being tested in this study is called NoV GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide. The norovirus vaccine is being tested to prevent AGE due to genotype-specific (GI.1 and GII.4) norovirus strains in healthy participants recruited from a US military training installation. This study will look at the illness rate of AGE occurring \\> 7 days after dosing due to genotype-specific (GI.1 or GII.4) NoV strains represented in the vaccine.\n\nThe study will enroll between 2800 and 8700 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):\n\n* Norovirus GI.1/GII.4 Bivalent VLP Vaccine\n* Placebo (dummy inactive solution) - this is a liquid that looks similar to the study drug but has no active ingredient\n\nAll participants will receive one dose of study medication on Day 1 administered via intramuscular injection.\n\nThis multi-center trial will be conducted in the United States at select military locations. The overall time to participate in this study is up to 45 days for participants in the navy 53 days for participants in the Air Force, and 72 days for participants in the marines. Participants will make multiple visits to the clinic, including a final visit on the last day of study participation (Day 45, 53 or 72) for a follow-up assessment."},"conditionsModule":{"conditions":["Healthy Volunteers"],"keywords":["Drug therapy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":4748,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"NoV placebo-matching 0.5 mL solution for injection, intramuscularly (IM), once, on Day 1.","interventionNames":["Biological: NoV Placebo-matching Saline"]},{"label":"NoV GI.1/GII.4 Bivalent VLP Vaccine","type":"EXPERIMENTAL","description":"NoV GI.1/GII.4 bivalent virus-like particle (VLP) vaccine, 0.5 mL injection, intramuscularly (IM), once, on Day 1.","interventionNames":["Biological: NoV GI.1/GII.4 Bivalent VLP Vaccine"]}],"interventions":[{"type":"BIOLOGICAL","name":"NoV Placebo-matching Saline","description":"NoV placebo-matching saline (0.9% sodium chloride).","armGroupLabels":["Placebo"]},{"type":"BIOLOGICAL","name":"NoV GI.1/GII.4 Bivalent VLP Vaccine","description":"NoV bivalent VLP vaccine, adjuvanted with 500 µg aluminum as Al(OH)3.","armGroupLabels":["NoV GI.1/GII.4 Bivalent VLP Vaccine"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Moderate or Severe Acute Gastroenteritis (AGE) Occurring for >7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Excluding Co-infection)","description":"Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by reverse transcriptase polymerase chain reaction (RT-PCR). The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains excluding co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.","timeFrame":"Up to Day 47"}],"secondaryOutcomes":[{"measure":"Number of Participants With Moderate or Severe AGE Occurring >7 Days After Dosing Due to Any Norovirus Strain (Excluding Co-infection)","description":"Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by RT-PCR. The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains excluding co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.","timeFrame":"Up to Day 47"},{"measure":"Number of Participants With Moderate or Severe AGE Occurring >7 Days After Dosing Due to Any Norovirus Strain (Including Co-infection)","description":"Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by RT-PCR. The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains including co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.","timeFrame":"Up to Day 47"},{"measure":"Number of Participants With Moderate or Severe AGE Occurring >7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Including Co-infection)","description":"Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by RT-PCR. The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains including co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.","timeFrame":"Up to Day 47"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any trial procedures after the nature of the trial has been explained according to local regulatory requirements.\n2. Male or female participants, 18 to 49 years of age.\n3. Is in good health at the time of entry into the trial as determined by medical history and the clinical judgment of the investigator.\n4. Can comply with trial procedures and are available for the duration of follow-up.\n\nExclusion Criteria:\n\n1. Pregnancy.\n2. Has known hypersensitivity to any of the Norovirus (NoV) GI.1/GII.4 bivalent virus-like particle (VLP) vaccine components (including excipients).\n3. Has known hypersensitivity or allergy to any of the licensed required concomitant vaccine components to be administered (including excipients of these vaccines).\n4. Has any condition or circumstance that the investigator determines would interfere with trial evaluation or interpretation.\n5. Has known or suspected impairment or alteration of immune function.\n6. Has a history of acute gastroenteritis (AGE) within 14 days of enrollment.\n7. Has a history of body temperature of 38.0°C (100.4°F) or higher within 3 days of intended trial vaccination.\n8. Has received blood, blood products, and/or plasma derivatives or any parenteral immunoglobulin antibody preparation in the past 3 months.\n9. Immunosuppressive therapy within 3 months or systemic (e.g., oral or parenteral) corticosteroid treatment within 60 days prior to investigational trial dose administration.\n10. Is participating in any clinical trial with another investigational product 30 days prior to the first trial visit or intending to participate in another clinical trial at any time during the conduct of this trial.\n11. Participants who are first-degree relatives of individuals involved in the conduct of the trial.\n12. Has any history of progressive or severe neurologic disorder, seizure disorder or neuro-inflammatory disease (e.g. Guillain-Barré syndrome).\n13. Has history or any illness that, in the opinion of the investigator, might interfere with the results of the trial or pose additional risk to the participants due to participation in the trial.\n14. Has received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in this trial with the exception of routine immunizations as per Military Procedures.\n15. If female of childbearing potential, sexually active, and has not used any of the \"acceptable contraceptive methods\" for at least 2 months prior to trial entry:\n\n    1. Of childbearing potential is defined as status post onset of menarche and not meeting any of the following conditions: menopausal for at least 2 years, status after bilateral tubal ligation for at least 1 year, status after bilateral oophorectomy, or status after hysterectomy.\n    2. Acceptable birth control methods are defined as one or more of the following:\n\n       * Hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical ring).\n       * Barrier (condom with spermicide or diaphragm with spermicide) each and every time during intercourse.\n       * Intrauterine device (IUD).\n       * Monogamous relationship with vasectomized partner. Partner must have been vasectomized for at least six months prior to the participants' trial entry.\n16. If female of childbearing potential and sexually active, refusal to use an \"acceptable contraceptive method\" from Day 1 through 6 months after the last dose of trial vaccine. In addition, they must be advised not to donate ova during this period.\n17. Has any positive or indeterminate pregnancy test.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Study Director","affiliation":"Takeda","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Great Lakes Naval Station","city":"Great Lakes","state":"Illinois","zip":"60088","country":"United States","geoPoint":{"lat":42.30919,"lon":-87.85007}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR"],"accessCriteria":"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.","url":"https://vivli.org/ourmember/takeda/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Healthy volunteers were enrolled in the study and randomized in 1:1 ratio to receive Norovirus GI.1/GII.4 Bivalent VLP Vaccine or Placebo.","recruitmentDetails":"Participants took part in the study at a single investigative site in the United States from 14 June 2016 to 16 June 2018.","groups":[{"id":"FG000","title":"Placebo","description":"NoV placebo-matching 0.5 mL solution for injection, intramuscularly (IM), once, on Day 1."},{"id":"FG001","title":"NoV GI.1/GII.4 Bivalent VLP Vaccine","description":"NoV GI.1/GII.4 bivalent virus-like particle (VLP) vaccine, 0.5 mL injection, intramuscularly (IM), once, on Day 1."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"2377"},{"groupId":"FG001","numSubjects":"2371"}]},{"type":"Treated (Safety Analysis Set)","comment":"All participants who received trial vaccination (NoV or placebo).","achievements":[{"groupId":"FG000","numSubjects":"2357"},{"groupId":"FG001","numSubjects":"2355"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2087"},{"groupId":"FG001","numSubjects":"2089"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"290"},{"groupId":"FG001","numSubjects":"282"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"27"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"132"},{"groupId":"FG001","numSubjects":"140"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Discharged from US Military Active Service","reasons":[{"groupId":"FG000","numSubjects":"117"},{"groupId":"FG001","numSubjects":"91"}]},{"type":"Reason not Specified","reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"18"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Randomized Set included all enrolled participants.","groups":[{"id":"BG000","title":"Placebo","description":"NoV placebo-matching 0.5 mL solution for injection, IM, once, on Day 1."},{"id":"BG001","title":"NoV GI.1/GII.4 Bivalent VLP Vaccine","description":"NoV GI.1/GII.4 bivalent VLP vaccine, 0.5 mL injection, IM, once, on Day 1."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"2377"},{"groupId":"BG001","value":"2371"},{"groupId":"BG002","value":"4748"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20.3","spread":"2.95"},{"groupId":"BG001","value":"20.2","spread":"2.74"},{"groupId":"BG002","value":"20.3","spread":"2.85"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"423"},{"groupId":"BG001","value":"437"},{"groupId":"BG002","value":"860"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"1954"},{"groupId":"BG001","value":"1934"},{"groupId":"BG002","value":"3888"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"521"},{"groupId":"BG001","value":"484"},{"groupId":"BG002","value":"1005"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1856"},{"groupId":"BG001","value":"1887"},{"groupId":"BG002","value":"3743"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"56"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"88"},{"groupId":"BG002","value":"175"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"49"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"351"},{"groupId":"BG001","value":"355"},{"groupId":"BG002","value":"706"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"1668"},{"groupId":"BG001","value":"1667"},{"groupId":"BG002","value":"3335"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"165"},{"groupId":"BG001","value":"146"},{"groupId":"BG002","value":"311"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"116"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"2377"},{"groupId":"BG001","value":"2371"},{"groupId":"BG002","value":"4748"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Moderate or Severe Acute Gastroenteritis (AGE) Occurring for >7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Excluding Co-infection)","description":"Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by reverse transcriptase polymerase chain reaction (RT-PCR). The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains excluding co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.","populationDescription":"Full Analysis Set included all participants who were randomized and received the trial dose.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 47","groups":[{"id":"OG000","title":"Placebo","description":"NoV placebo-matching 0.5 mL solution for injection, IM, once, on Day 1."},{"id":"OG001","title":"NoV GI.1/GII.4 Bivalent VLP Vaccine","description":"NoV GI.1/GII.4 bivalent VLP vaccine, 0.5 mL injection, IM, once, on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2357"},{"groupId":"OG001","value":"2355"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Cox Proportional Hazard","paramValue":"0.800","ciPctValue":"99.99","ciNumSides":"TWO_SIDED","ciLowerLimit":"-13.181","ciUpperLimit":"0.997","otherAnalysisDescription":"The vaccine efficacy was met if lower bound of confidence interval (CI) for vaccine efficacy was above 0. Vaccine efficacy (VE) was defined as 1-(hazard rate for NoV vaccine arm / hazard rate for placebo arm), where the hazard ratio is from the Cox proportional hazard (PH) model. The 99.99% CI for the VE was obtained by taking 1 minus the 99.99% CI of the hazard ratio from the PH model."}]},{"type":"SECONDARY","title":"Number of Participants With Moderate or Severe AGE Occurring >7 Days After Dosing Due to Any Norovirus Strain (Excluding Co-infection)","description":"Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by RT-PCR. The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains excluding co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.","populationDescription":"Full Analysis Set included all participants who were randomized and received the trial dose.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 47","groups":[{"id":"OG000","title":"Placebo","description":"NoV placebo-matching 0.5 mL solution for injection, IM, once, on Day 1."},{"id":"OG001","title":"NoV GI.1/GII.4 Bivalent VLP Vaccine","description":"NoV GI.1/GII.4 bivalent VLP vaccine, 0.5 mL injection, IM, once, on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2357"},{"groupId":"OG001","value":"2355"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"10"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Cox Proportional Hazard","paramValue":"0.618","ciPctValue":"95.01","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.208","ciUpperLimit":"0.816","otherAnalysisDescription":"The vaccine efficacy was met if lower bound of CI for vaccine efficacy was above 0. Vaccine efficacy (VE) was defined as 1-(hazard rate for NoV vaccine arm / hazard rate for placebo arm), where the hazard ratio is from the PH model. The 95.01% CI for the VE was obtained by taking 1 minus the 95.01% CI of the hazard ratio from the PH model."}]},{"type":"SECONDARY","title":"Number of Participants With Moderate or Severe AGE Occurring >7 Days After Dosing Due to Any Norovirus Strain (Including Co-infection)","description":"Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by RT-PCR. The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains including co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.","populationDescription":"Full Analysis Set included all participants who were randomized and received the trial dose.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 47","groups":[{"id":"OG000","title":"Placebo","description":"NoV placebo-matching 0.5 mL solution for injection, IM, once, on Day 1."},{"id":"OG001","title":"NoV GI.1/GII.4 Bivalent VLP Vaccine","description":"NoV GI.1/GII.4 bivalent VLP vaccine, 0.5 mL injection, IM, once, on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2357"},{"groupId":"OG001","value":"2355"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"10"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Cox Proportional Hazard","paramValue":"0.618","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.208","ciUpperLimit":"0.816","otherAnalysisDescription":"The vaccine efficacy was met if lower bound of CI for vaccine efficacy was above 0. Vaccine efficacy (VE) was defined as 1-(hazard rate for NoV vaccine arm / hazard rate for placebo arm), where the hazard ratio is from the PH model. The 95% CI for the VE was obtained by taking 1 minus the 95% CI of the hazard ratio from the PH model."}]},{"type":"SECONDARY","title":"Number of Participants With Moderate or Severe AGE Occurring >7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Including Co-infection)","description":"Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by RT-PCR. The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains including co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.","populationDescription":"Full Analysis Set included all participants who were randomized and received the trial dose.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 47","groups":[{"id":"OG000","title":"Placebo","description":"NoV placebo-matching 0.5 mL solution for injection, IM, once, on Day 1."},{"id":"OG001","title":"NoV GI.1/GII.4 Bivalent VLP Vaccine","description":"NoV GI.1/GII.4 bivalent VLP vaccine, 0.5 mL injection, IM, once, on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2357"},{"groupId":"OG001","value":"2355"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Cox Proportional Hazard","paramValue":"0.800","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.711","ciUpperLimit":"0.977","otherAnalysisDescription":"The vaccine efficacy was met if lower bound of CI for vaccine efficacy was above 0. Vaccine efficacy (VE) was defined as 1-(hazard rate for NoV vaccine arm / hazard rate for placebo arm), where the hazard ratio is from the PH model. The 95% CI for the VE was obtained by taking 1 minus the 95% CI of the hazard ratio from the PH model."}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"From Day 1 up to the end of the study (Up to 47 days)","description":"At each visit investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by participant or observed by investigator was recorded, irrespective of relation to study treatment. Safety Analysis Set included all participants who received trial dose (NoV GI.1/GII.4 bivalent VLP vaccine or saline placebo).","eventGroups":[{"id":"EG000","title":"Placebo","description":"NoV placebo-matching 0.5 mL solution for injection, IM, once, on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":2357,"seriousNumAffected":35,"seriousNumAtRisk":2357,"otherNumAffected":88,"otherNumAtRisk":2357},{"id":"EG001","title":"NoV GI.1/GII.4 Bivalent VLP Vaccine","description":"NoV GI.1/GII.4 bivalent VLP vaccine, 0.5 mL injection, IM, once, on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":2355,"seriousNumAffected":29,"seriousNumAtRisk":2355,"otherNumAffected":98,"otherNumAtRisk":2355}],"seriousEvents":[{"term":"Microcytic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2357},{"groupId":"EG001","numAffected":1,"numAtRisk":2355}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Crohn's disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2357},{"groupId":"EG001","numAffected":1,"numAtRisk":2355}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2357},{"groupId":"EG001","numAffected":2,"numAtRisk":2355}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":2,"numAtRisk":2355}]},{"term":"Cellulitis staphylococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2357},{"groupId":"EG001","numAffected":2,"numAtRisk":2355}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2357},{"groupId":"EG001","numAffected":2,"numAtRisk":2355}]},{"term":"Infectious mononucleosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Abscess jaw","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Abscess oral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Chlamydial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Gastroenteritis clostridial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2357},{"groupId":"EG001","numAffected":1,"numAtRisk":2355}]},{"term":"Helicobacter gastritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Helicobacter infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2357},{"groupId":"EG001","numAffected":1,"numAtRisk":2355}]},{"term":"Parotitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Staphylococcal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2357},{"groupId":"EG001","numAffected":1,"numAtRisk":2355}]},{"term":"Tonsillitis streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2357},{"groupId":"EG001","numAffected":1,"numAtRisk":2355}]},{"term":"Varicella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2357},{"groupId":"EG001","numAffected":1,"numAtRisk":2355}]},{"term":"Muscle strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2357},{"groupId":"EG001","numAffected":1,"numAtRisk":2355}]},{"term":"Post procedural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2357},{"groupId":"EG001","numAffected":1,"numAtRisk":2355}]},{"term":"Rhabdomyolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2357},{"groupId":"EG001","numAffected":3,"numAtRisk":2355}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2357},{"groupId":"EG001","numAffected":1,"numAtRisk":2355}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2357},{"groupId":"EG001","numAffected":1,"numAtRisk":2355}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2357},{"groupId":"EG001","numAffected":1,"numAtRisk":2355}]},{"term":"Myelopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Adjustment disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":2357},{"groupId":"EG001","numAffected":2,"numAtRisk":2355}]},{"term":"Adjustment disorder with depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":3,"numAtRisk":2355}]},{"term":"Depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2357},{"groupId":"EG001","numAffected":2,"numAtRisk":2355}]},{"term":"Major depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":1,"numAtRisk":2355}]},{"term":"Persistent depressive disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":1,"numAtRisk":2355}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2357},{"groupId":"EG001","numAffected":1,"numAtRisk":2355}]},{"term":"Panic attack","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Bronchial hyperreactivity","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]},{"term":"Angioedema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2357},{"groupId":"EG001","numAffected":0,"numAtRisk":2355}]}],"otherEvents":[{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":45,"numAtRisk":2357},{"groupId":"EG001","numAffected":57,"numAtRisk":2355}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0 Mixed","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":57,"numAtRisk":2357},{"groupId":"EG001","numAffected":55,"numAtRisk":2355}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property."},"pointOfContact":{"title":"Study Director","organization":"Takeda","email":"TrialDisclosures@takeda.com","phone":"+1-877-825-3327"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2017-11-15","uploadDate":"2021-05-14T10:06","filename":"Prot_000.pdf","size":17566693},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-06-14","uploadDate":"2021-05-14T10:06","filename":"SAP_001.pdf","size":12495915}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"}},"hasResults":true}